Your browser doesn't support javascript.
loading
Potent and selective binders of the E3 ubiquitin ligase ZNRF3 stimulate Wnt signaling and intestinal organoid growth.
Kschonsak, Yvonne T; Gao, Xinxin; Miller, Stephen E; Hwang, Sunhee; Marei, Hadir; Wu, Ping; Li, Yanjie; Ruiz, Karen; Dorighi, Kristel; Holokai, Loryn; Perampalam, Pirunthan; Tsai, Wen-Ting K; Kee, Yee-Seir; Agard, Nicholas J; Harris, Seth F; Hannoush, Rami N; de Sousa E Melo, Felipe.
Afiliação
  • Kschonsak YT; Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address: kschonsy@gene.com.
  • Gao X; Department of Early Discovery Biochemistry and Peptide Therapeutics, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address: gaox7@gene.com.
  • Miller SE; Department of Early Discovery Biochemistry and Peptide Therapeutics, Genentech Inc, South San Francisco, CA 94080, USA.
  • Hwang S; Department of Early Discovery Biochemistry and Peptide Therapeutics, Genentech Inc, South San Francisco, CA 94080, USA.
  • Marei H; Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA.
  • Wu P; Department of Structural Biology, Genentech Inc, South San Francisco, CA 94080, USA.
  • Li Y; Department of Early Discovery Biochemistry and Peptide Therapeutics, Genentech Inc, South San Francisco, CA 94080, USA.
  • Ruiz K; Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA.
  • Dorighi K; Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080, USA.
  • Holokai L; Department of Biomarker Discovery, Genentech Inc, South San Francisco, CA 94080, USA.
  • Perampalam P; ProCogia Inc. under contract to Hoffmann-La Roche Limited, Toronto, Ontario M5J2P1, Canada.
  • Tsai WK; Department of Antibody Engineering, Genentech Inc, South San Francisco, CA 94080, USA.
  • Kee YS; Department of Antibody Engineering, Genentech Inc, South San Francisco, CA 94080, USA.
  • Agard NJ; Department of Antibody Engineering, Genentech Inc, South San Francisco, CA 94080, USA.
  • Harris SF; Department of Structural Biology, Genentech Inc, South San Francisco, CA 94080, USA.
  • Hannoush RN; Department of Early Discovery Biochemistry and Peptide Therapeutics, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address: ramihannoush@gmail.com.
  • de Sousa E Melo F; Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address: desousaf@gene.com.
Cell Chem Biol ; 2023 Dec 05.
Article em En | MEDLINE | ID: mdl-38056465
Selective and precise activation of signaling transduction cascades is key for cellular reprogramming and tissue regeneration. However, the development of small- or large-molecule agonists for many signaling pathways has remained elusive and is rate limiting to realize the full clinical potential of regenerative medicine. Focusing on the Wnt pathway, here we describe a series of disulfide-constrained peptides (DCPs) that promote Wnt signaling activity by modulating the cell surface levels of ZNRF3, an E3 ubiquitin ligase that controls the abundance of the Wnt receptor complex FZD/LRP at the plasma membrane. Mechanistically, monomeric DCPs induce ZNRF3 ubiquitination, leading to its cell surface clearance, ultimately resulting in FZD stabilization. Furthermore, we engineered multimeric DCPs that induce expansive growth of human intestinal organoids, revealing a dependence between valency and ZNRF3 clearance. Our work highlights a strategy for the development of potent, biologically active Wnt signaling pathway agonists via targeting of ZNRF3.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article